Open Payments

Childrens Hospital

Type
Teaching hospital
Where
Washington, DC
Medicare CCN
093300
Received
$1,537,805 in 96 records, 2025 ($783,952 general, $753,852 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment30$783,952
2025Research payment66$753,852

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation17$736,0112025
Takeda Pharmaceuticals U.S.A., Inc.2$654,0002025
MED-EL Corporation1$66,1402025
Berlin Heart Inc2$15,2702025
QIAGEN, LLC1$10,0002025
National Marrow Donor Program5$8,9152025
Siemens Medical Solutions USA, Inc.2$5,1912025
Merck Sharp & Dohme LLC2$5,0002025
PFIZER INC.2$5,0002025
Neurelis, Inc.2$4,2002025
Baxter Healthcare2$4,1282025
Regeneron Healthcare Solutions, Inc.1$4,0002025
Haemonetics Corporation1$3,6862025
Abbott Laboratories1$3,5002025
Mallinckrodt Hospital Products Inc.1$3,5002025
AstraZeneca Pharmaceuticals LP1$2,5002025
SANOFI-AVENTIS U.S. LLC1$2,5002025
Bio-Rad Laboratories, Inc.2$1,0162025
OrthoPediatrics Corp.1$1,0002025
JAZZ PHARMACEUTICALS INC.41$9572025
Linvatec Corporation1$5062025
Dexcom, Inc.1$3692025
Incyte Corporation4$2442025
Olympus America Inc.2$1682025

By nature of payment

NatureRecordsAmount
Research payment66$753,852
Grant4$661,200
Long term medical supply or device loan2$66,646
Space rental or facility fees (teaching hospital only)9$35,000
Compensation for services other than consulting, including serving as faculty or as a speaker at a v7$13,869
Debt forgiveness6$4,236
Education1$2,000
Consulting Fee1$1,000

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Siemens Medical Solutions USA, Inc.$191Debt forgivenessIn-kind items and services2025
2025-12-09Mallinckrodt Hospital Products Inc.$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentINOMAX Drug, CRITICAL CARE2025
2025-12-09Novartis Pharmaceuticals Corporation$2,348Research paymentCash or cash equivalentA single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic2025
2025-12-08JAZZ PHARMACEUTICALS INC.$21Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-12-08JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-12-08JAZZ PHARMACEUTICALS INC.$3Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-12-04Merck Sharp & Dohme LLC$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentROTATEQ Biological, VACCINE2025
2025-11-19Novartis Pharmaceuticals Corporation$326,960Research paymentIn-kind items and servicesPIQRAY Drug, OncologyEPIK-L1: a phase II/III double-blind, randomized, placebo-controlled study to assess the efficacy, safety and pharmacoki2025
2025-11-18AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentFLUMIST QUADRIVALENT Biological, Respiratory2025
2025-11-17PFIZER INC.$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-11-15Novartis Pharmaceuticals Corporation$8,937Research paymentIn-kind items and servicesKYMRIAH Drug, OncologyA single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic2025
2025-11-05Bio-Rad Laboratories, Inc.$62Debt forgivenessCash or cash equivalentIH Systems Device, Not Applicable2025
2025-10-28Berlin Heart Inc$7,650Research paymentCash or cash equivalent DeviceEXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study2025
2025-10-24National Marrow Donor Program$1,000Research paymentCash or cash equivalentA Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research2025
2025-10-17National Marrow Donor Program$890Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-15Baxter Healthcare$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentTISSEEL Biological, Surgical Care2025
2025-10-14QIAGEN, LLC$10,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-09-30Olympus America Inc.$20Debt forgivenessIn-kind items and servicesCOMMUNICATION CABLE 1.8M Device, Gastroenterology2025
2025-09-25Novartis Pharmaceuticals Corporation$18,375Research paymentCash or cash equivalentA phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with2025
2025-09-19Siemens Medical Solutions USA, Inc.$5,000GrantCash or cash equivalent2025
2025-09-15Novartis Pharmaceuticals Corporation$91Research paymentIn-kind items and servicesKYMRIAH Drug, OncologyA single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic2025
2025-09-10Haemonetics Corporation$3,686Debt forgivenessCash or cash equivalent2025
2025-09-04Novartis Pharmaceuticals Corporation$2,980Research paymentCash or cash equivalentTAFINLAR Drug, OncologyAn Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabr2025
2025-08-21Novartis Pharmaceuticals Corporation$37,591Research paymentCash or cash equivalentADAKVEO Drug, HematologyAn Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2025
2025-08-08Incyte Corporation$91Research paymentCash or cash equivalentA study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease2025
2025-08-08Incyte Corporation$64Research paymentCash or cash equivalentA study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease2025
2025-08-08Incyte Corporation$59Research paymentCash or cash equivalentA study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease2025
2025-08-08Incyte Corporation$29Research paymentCash or cash equivalentA study to evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease2025
2025-07-23National Marrow Donor Program$3,640Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-07-09JAZZ PHARMACEUTICALS INC.$42Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$35Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$35Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-07-09JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-06-30Olympus America Inc.$147Debt forgivenessIn-kind items and services2025
2025-06-24Novartis Pharmaceuticals Corporation$9,275Research paymentCash or cash equivalentZOLGENSMA Drug, NeurologyRetrospective Chart Review of Zolgensma (onasemnogene abeparvovec) Intravenous (IV) in Spinal Muscular Atrophy (SMA) pat2025
2025-06-16Regeneron Healthcare Solutions, Inc.$4,000GrantCash or cash equivalentDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-06-02Novartis Pharmaceuticals Corporation$12,009Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesTwo Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multice2025
2025-06-02Novartis Pharmaceuticals Corporation$11,916Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesTwo Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multice2025
2025-05-29Merck Sharp & Dohme LLC$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentPROQUAD Biological, VACCINE2025
2025-05-29SANOFI-AVENTIS U.S. LLC$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentTZIELD Biological, Endocrine & Metabolic Diseases2025
2025-05-16PFIZER INC.$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentTRUMENBA Biological, VACCINES2025
2025-04-25Neurelis, Inc.$2,000EducationCash or cash equivalentVALTOCO Drug, EPILEPSY2025
2025-04-25National Marrow Donor Program$1,115Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-10Linvatec Corporation$506Long term medical supply or device loanIn-kind items and servicesHALL POWER Device, ORTHOPEDIC SURGERY2025
2025-04-08JAZZ PHARMACEUTICALS INC.$27Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-04-08JAZZ PHARMACEUTICALS INC.$9Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-04-08JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-04-08JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-04-08JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-04-08JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-04-04Takeda Pharmaceuticals U.S.A., Inc.$4,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-03-28Baxter Healthcare$128Debt forgivenessIn-kind items and services Device, Trauma (Emergency, Injury, Surgery)2025
2025-03-20MED-EL Corporation$66,140Long term medical supply or device loan (8 payments)In-kind items and servicesMi1250 SYNCHRONY 2 FLEXsoft Device, Cochlear Implant2025
2025-03-19Bio-Rad Laboratories, Inc.$954Compensation for services other than consulting, including serving as faculty or as a speaker at a vIn-kind items and servicesAntibody Device, Market Research2025
2025-03-17Neurelis, Inc.$2,200GrantCash or cash equivalentVALTOCO Drug, EPILEPSY2025
2025-03-12Novartis Pharmaceuticals Corporation$70,806Research paymentIn-kind items and servicesXOLAIR Drug, Pulmonary/Respiratory DiseasesOmalizumab Before Onset of Exacerbations URI-induc. asthma exacerbation2025
2025-03-10Dexcom, Inc.$369Research paymentIn-kind items and servicesDexcom G6 Transmitter Medical Supply, EndocrinologyCAMP: CGM-Assisted Management of PN2025
2025-03-10JAZZ PHARMACEUTICALS INC.$127Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$106Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$68Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$54Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$42Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$42Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$42Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$42Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$20Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$4Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$4Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-10JAZZ PHARMACEUTICALS INC.$4Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-03-06Novartis Pharmaceuticals Corporation$45,318Research paymentCash or cash equivalentTAFINLAR Drug, OncologyAn Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabr2025
2025-03-06Novartis Pharmaceuticals Corporation$12,027Research paymentCash or cash equivalentMAYZENT Drug, NeurologyA 2-year Randomized, 3-arm, Double-blind, Non-inferiority Study Comparing the Efficacy and Safety of Ofatumumab and Sipo2025
2025-03-05OrthoPediatrics Corp.$1,000Consulting FeeCash or cash equivalent2025
2025-03-01Novartis Pharmaceuticals Corporation$9,882Research paymentCash or cash equivalentADAKVEO Drug, HematologyA Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizu2025
2025-02-24Abbott Laboratories$3,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Structural Heart2025
2025-02-10Berlin Heart Inc$7,620Research paymentCash or cash equivalent DeviceEXCOR Active Driving System for the EXCOR Pediatric VAD IDE Study2025
2025-02-10JAZZ PHARMACEUTICALS INC.$23Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$11Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-02-10JAZZ PHARMACEUTICALS INC.$7Research paymentCash or cash equivalentZEPZELCA Drug, HEMATOLOGY/ONCOLOGYA Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP22025
2025-01-30Novartis Pharmaceuticals Corporation$36,035Research paymentCash or cash equivalentA One Month, Investigator and Participant Blinded Study to Investigate the Efficacy and Safety of Remibrutinib (LOU064) 2025
2025-01-24National Marrow Donor Program$2,270Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-01-20Takeda Pharmaceuticals U.S.A., Inc.$650,000GrantCash or cash equivalent2025
2025-01-17Novartis Pharmaceuticals Corporation$3,750Research paymentCash or cash equivalentADAKVEO Drug, HematologyA phase 2 Multicenter Open Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab with or with2025
2025-01-14Novartis Pharmaceuticals Corporation$127,704Research paymentCash or cash equivalentADAKVEO Drug, HematologyAn Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior N2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

District of ColumbiaWashington city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Washington, DC, county District of Columbia, DC, state District of Columbia; placed by its city name.

MeasurePlace (city or town)
Washington, DC
County
District of Columbia, DC
State
District of Columbia
Population B01003681,294681,294681,294
Population, 2020 census P1689,545689,545689,545
Median age B0100234.934.934.9
Under 18 B0100118.7%18.7%18.7%
65 and over B0100112.8%12.8%12.8%
Households B11001324,491324,491324,491
Foreign born B0500214.3%14.3%14.3%
Median household income B19013$109,870$109,870$109,870
Median family income B19113$155,025$155,025$155,025
Per capita income B19301$77,348$77,348$77,348
Poverty rate B1700115.4%15.4%15.4%
Unemployment rate B230256.3%6.3%6.3%
Civilian labor force B23025400,406400,406400,406
Mean commute (minutes) B0801330.030.030.0
Bachelor's degree or higher B1500364.2%64.2%64.2%
Housing units B25001361,014361,014361,014
Owner-occupied B2500341.5%41.5%41.5%
Renters B2500358.5%58.5%58.5%
Median home value B25077$737,100$737,100$737,100
Median gross rent B25064$1,954$1,954$1,954
White, not Hispanic B0300236.5%36.5%36.5%
Black B0300241.6%41.6%41.6%
Hispanic or Latino B0300211.9%11.9%11.9%
Asian B030024.3%4.3%4.3%
American Indian and Alaska Native B030020.1%0.1%0.1%

Economy now FRED unemployment 5.6% in Sep 2026 (6.6% a year earlier); per capita personal income $119,772 in 2025, up 32% in five years (+6.5% after inflation); Unemployment rate: 6.3% in Sep 2016 to 5.6% in Sep 2026; low 4.0%, high 11.3% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Washington, DC.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.